SHP.L - Shire plc

LSE - LSE Delayed price. Currency in GBp
3,827.00
+7.00 (+0.18%)
At close: 6:37PM BST
Stock chart is not supported by your current browser
Previous close3,820.00
Open3,900.00
Bid3,820.00 x 51000
Ask3,900.00 x 53800
Day's range3,798.00 - 3,918.50
52-week range2,940.50 - 5,021.00
Volume5,684,278
Avg. volume4,680,926
Market cap34.64B
Beta1.27
PE ratio (TTM)8.18
EPS (TTM)468.00
Earnings date26 Feb 2018 - 28 Feb 2018
Forward dividend & yield0.25 (0.67%)
Ex-dividend date2018-03-08
1y target est64.37
  • Overshadowed by Takeda bid, Shire reports solid start to year
    Reuters12 hours ago

    Overshadowed by Takeda bid, Shire reports solid start to year

    London-listed drugmaker Shire (SHP.L) reported a solid start to the year on Thursday with first-quarter earnings up 6 percent despite challenges on several fronts as it works towards a deal to be acquired by Takeda Pharmaceutical . The rare-disease specialist said on Wednesday it was willing to support a $64 billion (46 billion pounds) offer from Takeda, in what would be the biggest takeover in the sector since 2000, but investors see risks to the ambitious deal being consummated. Takeda's falling share price has already reduced the value of the cash-and-shares deal to around $61.5 billion.

  • Reuters - UK Focus12 hours ago

    Overshadowed by Takeda bid, Shire reports solid start to year

    London-listed drugmaker Shire (Hamburg: 3979575.HM - news) reported a solid start to the year on Thursday with first-quarter earnings up 6 percent despite challenges on several fronts as it works towards a deal to be acquired by Takeda Pharmaceutical. The rare-disease specialist said on Wednesday it was willing to support a $64 billion offer from Takeda, in what would be the biggest takeover in the sector since 2000, but investors see risks to the ambitious deal being consummated. Takeda's falling share price has already reduced the value of the cash-and-shares deal to around $61.5 billion.

  • Associated Press12 hours ago

    Shire: 1Q Earnings Snapshot

    The Dublin-based company said it had profit of $1.81 per share. Earnings, adjusted for one-time gains and costs, came to $3.86 per share. The results surpassed Wall Street expectations. The average estimate ...

  • The Wall Street Journal13 hours ago

    [$$] Shire Sales Boost Profits, But No Comment on Takeda

    The drugmaker reported a 47% rise in first-quarter net profit on higher sales but made no comment on its possible takeover by Japan’s Takeda Pharmaceutical.

  • Business Wire15 hours ago

    Form 8.3 - SHIRE PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Takeda's $64 Billion Offer Bolstered by Shire's Results
    Bloomberg15 hours ago

    Takeda's $64 Billion Offer Bolstered by Shire's Results

    Shire Plc’s results topped expectations for its latest quarter, bolstering Takeda Pharmaceutical Co.’s case in selling its $64 billion takeover offer to investors.

  • Reuters - UK Focus16 hours ago

    Bid target Shire reports 6 pct rise in first-quarter earnings

    Shire, the London-listed drugmaker targeted by Takeda Pharmaceutical, reported a 6 percent rise in first-quarter earnings on Thursday, helped by higher product sales and a lower tax rate partially offset ...

  • GlobeNewswire16 hours ago

    Shire plc : 1st Quarter Results

      Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018   Growth driven by Immunology, recently-launched products, and international expansion   Innovative pipeline progresses ...

  • PR Newswire19 hours ago

    Norges Bank - Form 8.3 - Shire PLC

    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION ...

  • GlobeNewswire21 hours ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Business Wire21 hours ago

    Form 8.3 - Shire PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • The Wall Street Journal23 hours ago

    [$$] Takeda Nears Shire Deal as Japanese Companies Chase Growth Overseas

    Takeda is near a deal worth more than $60 billion to buy European drugmaker Shire, having raised its bid four times in a sign of how ardently Japan’s legacy companies are pursuing growth abroad as sales ...

  • Shire Says It's Willing To Entertain $64 Billion Bid From Takeda Pharma
    Investor's Business Dailyyesterday

    Shire Says It's Willing To Entertain $64 Billion Bid From Takeda Pharma

    Shire said late Tuesday it's willing to recommend a $64 billion takeover by Takeda Pharmaceuticals to shareholders before a new May 8 deadline.

  • Takeda Pharmaceutical Makes 4th Successive Bid for Shire
    Market Realistyesterday

    Takeda Pharmaceutical Makes 4th Successive Bid for Shire

    Takeda Pharmaceutical’s (TKPYY) bid for Shire (SHPG) has piqued a lot of investor interest. After three of Takeda’s previous bids were rejected, it announced a new bid of $60 billion for Shire on April 20. Takeda, a Japanese pharmaceutical company, has increased its offer to 47 pounds per share from 46.5 pounds per share.

  • Shire willing to back $64 billion Takeda bid, market signals doubts
    Reutersyesterday

    Shire willing to back $64 billion Takeda bid, market signals doubts

    LONDON/NEW YORK/TOKYO (Reuters) - Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000. The stock slide - 18 percent since the news of a possible bid broke - makes the cash-and-share deal less appealing to Shire shareholders, some of whom may be reluctant or unable to hold Takeda shares. "The chances are UK shareholders in particular are not going to want Takeda shares, so there’s going to be a forced discount because some people are going to sell it," said Neil Dwane, global strategist at Allianz Global Investors, which holds 1.1 percent of Shire, Thomson Reuters data showed.

  • Reutersyesterday

    Shire willing to back $64 billion Takeda bid, market signals doubts

    LONDON/NEW YORK/TOKYO (Reuters) - Rare disease specialist Shire said on Wednesday it was willing to recommend a sweetened $64 billion offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company since 2000. The stock slide - 18 percent since the news of a possible bid broke - makes the cash-and-share deal less appealing to Shire shareholders, some of whom may be reluctant or unable to hold Takeda shares. "The chances are UK shareholders in particular are not going to want Takeda shares, so there’s going to be a forced discount because some people are going to sell it," said Neil Dwane, global strategist at Allianz Global Investors, which holds 1.1 percent of Shire, Thomson Reuters data showed.

  • MarketWatchyesterday

    FTSE 100 breaks 6-day win streak after rising bond yields spur selloff on Wall Street

    U.K. stocks dropped Wednesday, with the blue-chip market’s winning streak coming to an end as elevated U.S. bond yields triggered a selloff on Wall Street.

  • Takeda's share price will make or break Shire deal, City says
    The Telegraphyesterday

    Takeda's share price will make or break Shire deal, City says

    Takeda's share price will make or break Shire deal, City says

  • GlobeNewswire2 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire2 days ago

    Shire plc : Shire announces revised proposal and extension of PUSU deadline to 8 May 2018

    THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE"). The revised proposal comprises 0.839 new Takeda shares and US$30.33 in cash for each Shire ordinary share (the "Revised Proposal").

  • Why Takeda's £46bn deal for Shire is not in the bag
    Sky News2 days ago

    Why Takeda's £46bn deal for Shire is not in the bag

    Whereas GKN employed thousands of skilled British workers, Shire employs fewer than 500 people in the UK, out of a global workforce of more than 24,000. It is, though, a remarkable success story. Shire was founded as recently as 1986 by the pharmaceuticals entrepreneur Harry Stratford and his wife Caroline.

  • PR Newswire2 days ago

    Norges Bank - Form 8.3 - Shire Plc

    FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1.         KEY INFORMATION ...

  • Reuters2 days ago

    Shire willing to back $64 billion Takeda bid, market signals doubts

    LONDON/NEW YORK/TOKYO (Reuters) - Rare disease specialist Shire (SHP.L) said on Wednesday it was willing to recommend a sweetened $64 billion (46 billion pounds) offer from Japan's Takeda Pharmaceutical Co to shareholders, in what would be the biggest acquisition of a drug company this year. The stock slide - 18 percent since the news of a possible bid broke - makes the cash-and-share deal less appealing to Shire shareholders, some of whom may be reluctant or unable to hold Takeda shares. "The chances are UK shareholders in particular are not going to want Takeda shares, so there’s going to be a forced discount because some people are going to sell it," said Neil Dwane, global strategist at Allianz Global Investors, which holds 1.1 percent of Shire, Thomson Reuters data showed.

  • Business Wire2 days ago

    Form 8.3 - SHIRE PLC

    LONDON--(BUSINESSWIRE)-- FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) ...

  • Associated Press2 days ago

    Drugmaker Takeda agrees to buy Shire for $64 billion

    LONDON (AP) — Japanese drugmaker Takeda has reached a tentative agreement to buy Ireland-based Shire for 46 billion pounds ($64 billion) in one of the biggest pharma deals to date.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes